Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Feb 6, 2013 - 3:55:15 PM



Compound Stimulates Tumor-fighting Protein in Cancer Therapy

By Staff Editor
Feb 6, 2013 - 3:52:25 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - HERSHEY, Pa. --A compound that stimulates the production of a tumor-fighting protein mayimprove the usefulness of the protein in cancer therapy, according to a team of researchers.

TRAIL is a natural anti-tumor protein that suppresses tumor development during immune surveillance -- theimmune system's process of patrolling the body for cancer cells. This process is lost during cancer progression, which leads to uncontrolled growth and spread of tumors.

The ability of TRAIL to initiate cell death selectively in cancer cells has led to ongoing clinical trials with artificially created TRAIL or antibody proteins that mimic its action. Use of the TRAIL protein as a drug has shown that it is safe, but there have been some issues, including stability of the protein, cost of the drug, and the ability of the drug to distribute throughout the body and get into tumors, especially in the brain.

"The TRAIL pathway is a powerful way to suppress tumors but current approaches have limitations that we have been trying to overcome to unleash an effective and selective cancer therapy," said Dr. Wafik El-Deiry, professor of medicine and chief of the hematology/oncology division, Penn State College of Medicine. "The TRAIL biochemical cell death pathway naturally lends itself as a drug target to restore anti-tumor immunity."

Researchers have identified a compound called TRAIL-inducing Compound 10 (TIC10) as a potential solution.TIC10 stimulates the tumor suppression capabilities of TRAIL in both normal and tumor tissues, including in the brain, and induces tumor cell death in mice. They report their findings in the journal Science Translational Medicine.

TIC10 is a small molecule. This organic compound binds to a protein and alters what the protein does.

Stimulation of TRAIL protein is sustained in both tumor and normal cells, with the normal cells contributing to the TIC10-induced cancer cell death through a bystander effect. It is effective in cancer cell samples and cell lines resistant to conventional therapies.

"I wassurprised and impressed that we were able to do this," El-Deiry said. "Using a small molecule to significantly boost and overcome limitations of the TRAIL pathway appears to be a promising way to address difficult to treat cancers using asafe mechanism already used in those with a normal effective immune system. This candidate new drug, a first-in-its-class, shows activity against a broad range of tumor types in mice and appears safe at this stage."

New treatments are needed for advanced cancer, as more than half a million people in the United States will die of cancer in 2013.

"We have enough preclinical information to support the rationale for testing this new drug in the clinic," El-Deirysaid.

TIC10 seems to be nontoxic to normal cells or mice even at doses 10 times higher that an observed therapeutic dose. However, more research needs to be completed to satisfy FDA requirements prior to initiation of clinical testing.

Other researchers are Joshua E. Allen, David T. Dicker, Akshal S. Patel, Nathan G. Dolloff, Kimberly A. Scata,Wenge Wang, all of Penn State Hershey Cancer Institute; Gabriel Krigsfeld, Patrick A. Mayes, Luv Patel, University of Pennsylvania School of Medicine; Evangelos Messaris, Department of Surgery, Penn State College Medicine; Jun-Ying Zhou and Gen Sheng Wu, Wayne State University School of Medicine.

This study was funded by the American Cancer Society, Penn State Hershey Cancer Institute and the National Institutes of Health.

###

 

For advertising and promotion on www.HealthNewsDigest.com contact Mike McCurdy at: [email protected]  or call 877-634-9180. We are syndicated worldwide and read in 164 countries. We also have over 7,000 journalists as subscribers who may use our content for their own media!

 

 

 



Top of Page

HealthNewsDigest.com

Cancer Issues
Latest Headlines


+ New Center to Broaden Cancer Disparities Research
+ Quitting Smoking Remains the Number One Way to Prevent Cancer
+ Surgery Plus Chemoradiation Linked to Improved Survival Rates for Gastric Cancer Patients
+ Cancer Researchers Identify Gene Mutations and Process for How Kidney Tumors Develop
+ Childhood Central Nervous System Cancer Affects Identity in Adulthood
+ Experience Trumps Convenience When Choosing a Cancer Surgeon
+ Understanding Ovarian Cancer: Know The Facts
+ Cancer Survivor’s Tips
+ The Top Five Advances In 50 Years Of Progress Against Cancer
+ Cervical Cancer: - Millions of US Women are Not Getting Screened



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions